Advanced Prostate Cancer Treatments Extend Survival as 38% 5-Year Rate Lags Newer Care
Updated
Updated · CNN · Jul 23
Advanced Prostate Cancer Treatments Extend Survival as 38% 5-Year Rate Lags Newer Care
3 articles · Updated · CNN · Jul 23
Summary
More men with metastatic prostate cancer are living longer because doctors now start combination treatment earlier, pairing hormone therapy with newer hormone blockers and sometimes chemotherapy.
The older 38% five-year relative survival rate for cancer that has spread reflects patients treated years ago and does not fully capture gains from newer drugs, imaging and tailored care.
PSMA PET scans are increasingly replacing traditional bone scans because they map spread more precisely, helping doctors distinguish low-volume from more widespread stage 4 disease and choose treatment accordingly.
Roughly 1 in 10 men with metastatic disease carries an inherited DNA-repair mutation that can open the door to PARP inhibitors, while PSMA-targeted radioligand therapy has also expanded for some hormone-resistant cases.
Biden’s Gleason 9, bone-spread, hormone-sensitive diagnosis has renewed attention on screening and on how advanced prostate cancer, while usually not curable once metastatic, can often be controlled for years.
New 'smart bomb' therapies hunt cancer cells. What is the next step when cancer adapts?
As cancer becomes a chronic illness, could stopping treatment become the new standard of care?
Prostate Cancer in 2026: Trends, Disparities, and the Future of Precision Medicine and Survivorship
Overview
Prostate cancer remains a major health challenge in 2026, with many cases being manageable but persistent disparities hindering overall progress in the U.S. Although men are diagnosed at much higher rates than they die from the disease, financial barriers like out-of-pocket costs still prevent many from accessing crucial screening and early detection. These disparities contribute to a significant national cancer burden, impacting the entire country. As a result, there is still considerable work needed to ensure that advances in cancer research and care benefit everyone, not just a select few.